LAS VEGAS, Aug. 4, 2014 /PRNewswire/ -- BioAdaptives, Inc.
(OTCBB:BDPT) announced results of the clinical trial completed on
"PRIMICELL™" which resulted in the research and development of 8
new products.
PRIMICELL™ is a trademarked name of the first product
BioAdaptives, Inc. will bring to market through private labeling
and exclusive licensing agreements worldwide. BioAdaptives, Inc.
Chairman and CEO, Barry Epling said,
"During the human clinical trial, glucose, routine hematology and
chemistry parameters, kidney function and liver function were
measured. The results demonstrated that no negative changes were
found, supporting the conclusion that PRIMICELL™ blend is
safe."
Epling added, "In addition to proving the product safe, the
participants who took PRIMICELL™ on average showed a 268% increase
of circulating, primitive stem cells. These results, coupled with
additional scientific studies on the product, have led us to begin
broader research on PRIMICELL and on 8 new, unique products in the
fields of anti-aging, sports recovery, weight-loss, assisting in
focus, lessening atherosclerosis, as well as regenerative help for
felines and canines. These products are each in a different
stage of development. Two are near completion in research and
development and will be brought to market soon."
With additional studies and trials continuing both in
the United States and Overseas,
Epling stated, "We are very excited at the findings to date and
each new study reveals new and valuable benefits, opening doors for
a wider array of products that can meaningfully better the lives of
both humans and animals. It is very exciting to be a part of
this."
About BioAdaptives, Inc.
BioAdaptives, Inc. is a fully-reporting, public company trading
on the OTC Bulletin Board under the symbol BDPT. The company is
engaged in research and development in science-based nutraceutical
products for human and animal consumption. The company's focus, in
conjunction with Ferris Holding,
Inc., is to source high quality, unique, raw material worldwide and
develop science-based products to improve
health and wellness in both humans and animals.
BioAdaptives, Inc., has developed a proprietary method that is a
non-intrusive bioelectromagnetic device for improving individual
ingredients, food, beverages, and wellness.
SAFE HARBOR ACT
Forward-Looking Statements: This release contains statements
that constitute forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. These
statements appear in a number of places in this release and include
all statements that are not statements of historical fact regarding
the intent, belief or current expectations of BioAdaptives, Inc. and its directors or
its officers with respect to, among other things: (i) financing
plans; (ii) trends affecting its financial condition or results of
operations; (iii) growth strategy and operating strategy. The words
"may," "would," "will," "expect," "estimate," "can," "believe,"
"potential" and similar expressions and variations thereof are
intended to identify forward-looking statements. Investors are
cautioned that any such forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties, many of which are beyond BioAdaptives, Inc.'s
ability to control, and actual results may differ materially from
those projected in the forward-looking statements as a result of
various factors. More information about the potential factors that
could affect the business and financial results is and will be
included in BioAdaptives, Inc.'s filings with the Securities and
Exchange Commission.
Investor Relations: (1) 888-280-0789
www.bioadaptives.com
SOURCE BioAdaptives, Inc.